MuTaTo by AEBi
Israeli pharmacists said they would have a full-fledged cancer cure within a year
Dmitry Mazalevsky, Naked Science
The Israeli pharmaceutical company Accelerated Evolution Biotechnologies (AEBi) claims that it will receive a "full-fledged cancer cure" in a year. Judging by the statements of the Chairman of the board, Dan Aridor, the approach that scientists are working on is revolutionary.
"Our cancer drug will be effective from day one, its effect will last for several weeks, and the drug itself will have no or only minimal side effects at a much lower cost than most other treatments on the market. The medicine can be taken both in general and in particular cases," Dan Aridor says in an interview with The Jerusalem Post: A cure for cancer? Israeli scientists say they think they.
According to available information, the AEBi cancer drug will be called MuTaTo, which means "multi-target toxin" (multi-target toxin). It attacks cancer cells with several peptides at once – compounds containing chains of amino acids, and it is this multifaceted attack that is the key to the effectiveness of treatment, the company said in a statement.
Israeli scientists have been working on systems to target toxins that would attack cancer cells. It is planned to achieve the desired result with the help of short protein fragments – peptides. In 2018, the Nobel Prize in Chemistry was awarded to the American George Smith, who back in the 1980s developed a method by which he was able to effectively select from a huge number of protein molecules those that have chemical affinity with the right receptors.
Israeli pharmacists went further: their method is based on smaller molecules, the purpose of which is not to destroy cancer cells, but to show the way to it, after which the cancer will be attacked by toxins. According to AEBi, the MuTaTo method is able to find an individual approach to a specific type of cancer in each patient.
Scientists have taken into account all factors to protect the course of treatment from the influence of mutations: cancer cells can change, producing target receptors. According to the CEO of AEBi Ilan Morad, the probability of having multiple mutations that could modify all target receptors simultaneously decreases dramatically with an increase in the number of targets used. In other words, instead of attacking one receptor at a time, the drug will attack three receptors at once. Even cancer cannot mutate in three receptors at the same time, says Morad.
According to the CEO of the company, AEBi has already tested a cancer drug for suppressing the growth of cancer cells in mice, without affecting healthy animal cells at all. In addition, Israeli researchers have also completed several in vitro tests (a technology for performing experiments when experiments are conducted "in vitro", that is, outside a living organism) and will soon begin clinical trials. It may take from six to seven years to transfer a drug from the laboratory to the real market, even though the drug manufacturers will receive all the necessary permits in time.
However, despite the optimism of the Israeli company, it is at least premature to claim the discovery of the long-awaited vaccine: the authors have not yet submitted any scientific papers on the basis of which any conclusions can be drawn, and the development itself, according to them, is only at the stage of patenting and initial experiments with mice. There is also nothing said about the deadlines for submitting an application to the appropriate authorities and approving the medicine by the medical board, and the only thing on which any conclusions can be drawn is the words of the company's representatives that after a series of tests that will be conducted "for several years", therapy will be possible only "in some specific cases".
Portal "Eternal youth" http://vechnayamolodost.ru